Prescient launches capital raise to progress pipeline of cancer therapies
Clinical stage oncology company Prescient Therapeutics to progress its deep pipeline of innovative cancer therapies...
Clinical stage oncology company Prescient Therapeutics to progress its deep pipeline of innovative cancer therapies...
Prescient has entered a deal with the manufacturing arm of the world-renowned QIMR Berghofer Medical...
It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. The...
The granting of an Orphan Drug Designation by the US FDA will grant PTX-100 market...
Prescient is continuing to be a powerful force in the burgeoning personalised cancer treatment therapy...
According to the World Health Organisation, cancer accounted for nearly 10 million deaths in 2020,...
Strong early indicators for the PTX-100 treatment give Prescient multiple pathways to market, as it...
Investors have plenty of exciting updates to look forward as PTX advances clinical trials and...
Is the leukemia busting CAR-T cell therapy, championed by Aussie-listed Prescient, the holy grail of...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.